Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DRD2 | P14416 | 4/20 | 0.43 |
| ▸ | HCRTR1 | O43613 | 1/20 | 0.42 |
| ▸ | NAAA | Q02083 | 2/20 | 0.41 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.41 |
| ▸ | TERT | O14746 | 2/20 | 0.39 |
| ▸ | CA12 | O43570 | 2/20 | 0.38 |
| ▸ | CA1 | P00915 | 2/20 | 0.38 |
| ▸ | CA2 | P00918 | 2/20 | 0.38 |
| ▸ | CA9 | Q16790 | 2/20 | 0.38 |
| ▸ | NPSR1 | Q6W5P4 | 2/20 | 0.38 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.38 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.38 |
| ▸ | MAPT | P10636 | 1/20 | 0.38 |
| ▸ | MAOA | P21397 | 1/20 | 0.37 |
| ▸ | MAOB | P27338 | 1/20 | 0.37 |
| ▸ | MALT1 | Q9UDY8 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20967806 | 0.89 | DRD2 (0.42) | DRD2HCRTR1TDP1TERTCA12 | |
| SCHEMBL18685252 | 0.83 | NAAA (0.45) | NAAATDP1CA12CA1CA2 | |
| SCHEMBL17038176 | 0.80 | TDP1 (0.49) | DRD2NAAATDP1CA12CA1 | |
| SCHEMBL17038124 | 0.76 | TDP1 (0.43) | DRD2TDP1CA12CA1CA2 | |
| SCHEMBL18685251 | 0.76 | CA1 (0.44) | TDP1CA12CA1CA2CA9 | |
| SCHEMBL17038117 | 0.75 | MAPT (0.41) | DRD2TDP1CA12CA1CA2 | |
| SCHEMBL16187635 | 0.70 | TDP1 (0.54) | TDP1CA12CA1CA2CA9 | |
| SCHEMBL25496763 | 0.70 | DRD2 (0.56) | DRD2TDP1CA12CA1CA2 | |
| SCHEMBL17038526 | 0.70 | TDP1 (0.51) | NAAATDP1CA12CA1CA2 | |
| SCHEMBL3523655 | 0.70 | TDP1 (0.60) | TDP1CA12CA1CA2CA9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240018174-A1 | QUINONE METHIDE ANALOG SIGNAL AMPLIFICATION | VENTANA MED SYST INC (US) | 2024-01-18 | — | — | US | disclosed |
| US-11780863-B2 | Quinone methide analog signal amplification | VENTANA MEDICAL SYSTEMS, INC. (US) | 2023-10-10 | — | — | US | disclosed |
| US-11365210-B2 | Quinone methide analog signal amplification | VENTANA MEDICAL SYSTEMS, INC. (US) | 2022-06-21 | — | — | US | disclosed |
| EP-3492919-A2 | QUINONE METHIDE ANALOG SIGNAL AMPLIFICATION | Ventana Medical Systems, Inc. (US) | 2019-06-05 | — | — | EP | disclosed |
| US-20190127405-A1 | QUINONE METHIDE ANALOG SIGNAL AMPLIFICATION | VENTANA MED SYST INC (US) | 2019-05-02 | — | — | US | disclosed |
| US-20190128893-A1 | QUINONE METHIDE ANALOG SIGNAL AMPLIFICATION | VENTANA MED SYST INC (US) | 2019-05-02 | — | — | US | disclosed |
| US-10168336-B2 | Quinone methide analog signal amplification | VENTANA MEDICAL SYSTEMS, INC. (US) | 2019-01-01 | — | — | US | disclosed |
| US-20170089911-A1 | QUINONE METHIDE ANALOG SIGNAL AMPLIFICATION | VENTANA MEDICAL SYSTEMS, INC. | 2017-03-30 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190128893-A1 | QUINONE METHIDE ANALOG SIGNAL AMPLIFICATION | NQO2, SQOR, MRM1 | DRD2 4351/4885HCRTR1 4727/4885NAAA 57/4885 |
| US-20190127405-A1 | QUINONE METHIDE ANALOG SIGNAL AMPLIFICATION | NQO2, SQOR, MRM1 | DRD2 4351/4885HCRTR1 4727/4885NAAA 57/4885 |
| US-11780863-B2 | Quinone methide analog signal amplification | NQO2, SQOR, MRM1 | DRD2 4351/4885HCRTR1 4727/4885NAAA 57/4885 |
| US-20240018174-A1 | QUINONE METHIDE ANALOG SIGNAL AMPLIFICATION | NQO2, SQOR, MRM1 | DRD2 4351/4885HCRTR1 4727/4885NAAA 57/4885 |
| US-20170089911-A1 | QUINONE METHIDE ANALOG SIGNAL AMPLIFICATION | NQO2, SQOR, MRM1 | DRD2 4351/4885HCRTR1 4727/4885NAAA 57/4885 |
| US-10168336-B2 | Quinone methide analog signal amplification | NQO2, SQOR, MRM1 | DRD2 4351/4885HCRTR1 4727/4885NAAA 57/4885 |
| US-11365210-B2 | Quinone methide analog signal amplification | NQO2, SQOR, MRM1 | DRD2 4351/4885HCRTR1 4727/4885NAAA 57/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.